All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld MedTech Perspectives » Rehash; FDA device inspections and the Guidant deal

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Rehash; FDA device inspections and the Guidant deal

Aug. 31, 2017
By Mark McCarty
No Comments

Not your average FDA inspector
Atypical FDA inspector

As the summer doldrums draw mercifully to a close, we can look back over a more or less expansive period of time to see where we’ve been in some hope of divining where things might be headed. Or maybe it’s just fun to revisit the past. In any event, following are a couple of developments of interest in the world of med tech.

Device warning letters tank

In case you were wondering whether industry pressure on the FDA regarding device inspections was having any effect, the jury is more or less back and the answer is, “it sure seems that way.”

You can’t have a warning letter without inspecting something, even if it’s just a company’s website, and the warning letters FDA posted on Aug. 29 include none for device makers. The list for Aug. 29 includes a number of warnings for drug-related GMP issues, while the most recent device warning letter is the July 12 warning to Whitehall Manufacturing, a letter from the Los Angeles district office. This is one of only two device warnings listed for the month of July.

Is this a big deal? One might think so, given that there are at least 10 warning letters to drug makers (and a fistful at least to compounding pharmacies) in July, and seven in August. The reader might remember all the noise about FDA inspections of device manufacturing sites, which led to provisions in the user fee legislation dealing with device inspections. Looks like industry has had a pretty serious impact on the volume of warning letters associated with those inspections as well.

Blast from a decade past

Sometimes it’s fun to scroll back and see where things stood 10 years ago, and the Aug. 31, 2007 issue of BioWorld MedTech – which at the time was still known as Medical Device Daily – reported on the settlement arrived at between Boston Scientific and a number of parties in connection with the company’s acquisition of the notorious Guidant.

As reported by our executive editor Holland Johnson, BSX had acquired Guidant the previous year for roughly $27 billion in an effort to gain traction in the cardiac electrophysiology space after something of a bidding war with other device makers. That deal cost the acquirer dearly in terms of  headaches, even if it seemed like a good idea at the time, but fast forward to just 30 months ago and there’s a press release describing the $600 million BSX had to hand over to Johnson & Johnson for Guidant’s purported breach of a merger agreement with J&J.

Was the Guidant buy worth all the headaches for BSX? Tough to say. By at least one account, Boston Sci had taken a total of nearly $13 billion in write-downs for the deal just by the end of 2012, but there were also lawsuits and an IRS tab to manage. Let’s not forget about the patent spat with Mirowski Family Ventures, a case that cost the company in excess of $300 million and which came to an end when the Supreme Court declined to grant cert for the case earlier this year.

Some have characterized the Guidant acquisition as the second worst deal of the century, but it’s still a young century! And even if everyone at BSX has concluded it really was a turkey of a deal after all, people in my line of work got almost as much mileage out of it as I managed to wring out of the acronym “SGR” before Congress laid it to rest. But that’s another story.

Son of hanging chad?

And now for some lighter fare. The Aug. 30 Medicare advisory committee was interesting for several reasons, including that the equipment used to tally votes once again came through in abysmal fashion. There were a number of instances in which a panelist’s vote did not register, although a review of the equipment may or may not disclose a digital piece of flotsam stuck to the electronic equivalent of a punch card.

We’ve seen this with FDA advisory committees, and it’s strictly a question of pressing a button, which makes a digital counter go up by one. You wouldn’t think that getting something like this to work is a Wernher von Braun moment, but…

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing